NASDAQ-GM · traded in Congress
AtriCure, ATRC
$58.54 -2.74 (-4.47%) Nov 6, 2026
Market value$3.0B
P/E ratio-
Analyst target$69.00
52-week range-
Avg volume1,120,681
Dividend yieldN/A
Chart
Analyst ratings
- 6 buy
- 3 hold
- 0 sell
Low target$57.00
Average target$66.75
High target$70.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $154M | $119M | $4M | 2.6% | |
| $154M | $119M | $9M | 5.8% | |
| $141M | $109M | $0M | 0.1% | |
| $141M | $105M | $2M | 1.3% |
Congress trades in ATRC
Members of Congress disclosed 3 transactions in ATRC in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 09/29/2026 | Gilbert Cisneros CA31 | Partial sale | $1,001 - $15,000 | 10/12/2026 filing |
| 08/20/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 9/10/2026 filing |
| 03/03/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 4/7/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
